Navigation Links
Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
Date:9/10/2007

Live Webcasts from New York on September 18th and 20th

SAN DIEGO, Sept. 10 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that Tamara Seymour, Chief Financial Officer, and David Guy, Chief Commercial Officer, will present at two upcoming investor conferences:

-- AG Edwards Emerging Growth Conference at 1:00 p.m. Eastern time on

Tuesday, September 18, 2007, from the New York Palace Hotel in New

York City; and

-- Wall Street Analyst Forum at 9:10 a.m. Eastern time on Thursday,

September 20, 2007, from the Princeton Club in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Live webcasts of both presentations can be accessed at http://www.favrille.com. Replays will be available approximately one hour after each presentation and archived for one month.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its results ... complete second quarter financial statements and MD&A have been filed on ... per shareThree-months ended , Six -months endedJune 30 , June 30 ... 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 , ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... Personalized Medicine, recently presented new data on the relationship of genetics and hypertension ... World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Jayne Garno, LSU associate professor of chemistry in the ... government,s highest honor for scientists and engineers in the ... Early Career Award for Scientists and Engineers, or PECASE. ... a prestigious award. LSU is a rich environment for ...
... DIEGO, Nov. 10, 2010 Anadys Pharmaceuticals, Inc. (Nasdaq: ... the Lazard 7th Annual Healthcare Conference on Wednesday, November 17, ... is being held at the St. Regis New York.  Steve ... provide an overview of Anadys and its clinical development programs. ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... the post-approval supplement to the PROVENGE® (sipuleucel-T) Biologics ... manufacturing facility. Dendreon is requesting licensure for an ... U.S. Food and Drug Administration (FDA) review for ...
Cached Biology Technology:LSU’s Jayne Garno receives early career award from President 2Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference 2Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility 2
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s touch ... 2015 that relate to sales of FPC1155 for this smartphone model ... for 2015. Jörgen Lantto, CEO of FPC, comments: " ... manufacturer in China and we are proud ... for Z1 , its first ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Listed below are the selected highlights for the November 2012 ... . The November issue is available online at ... November 2012, Copyright 2012. Please feel free to ... ISSUE HIGHLIGHTS , An ex vivo model ...
... metro region from Super Storm Sandy has not yet ... PhD, PE, says when the hammers start swinging, it,s ... The material, best known as AAC, has been heralded ... It,s a lightweight, easily-crafted manufactured stone, strong enough to ...
... researchers have discovered the cellular pathway that causes lung-damaging ... pathway,s activity also decreases inflammation. The finding offers ... disease, which is a major cause of illness and ... that target lung inflammation would be a big step ...
Cached Biology News:Genetics Society of America's GENETICS journal highlights for November 2012 2Genetics Society of America's GENETICS journal highlights for November 2012 3Genetics Society of America's GENETICS journal highlights for November 2012 4New drug target found for cystic fibrosis lung disease 2
... Anti-PSD-95, clone K28/86.2, PDZ Domain ... Immunogen : GST fusion to residues ... 0.01M Tris pH 7.4, 0.075M NaCl ... routinely evaluated by immunoblot on rat ...
... • Small design specifically for western blots ... are specifically designed for staining western blots. ... 25 mm) of the disposable tray requires ... significant cost savings to the user. Pour ...
... software has been designed and created in ... biologist friendly genotyping analysis tool. We incorporated ... groups into the software. Their main requirements ... and low acquisition cost. GeneMarker can ...
...
Biology Products: